Leading science and technology company Merck KGaA revealed that its Life Science division's ZooMAb recombinant antibody platform has been granted an Accountability, Consistency, and Transparency (ACT) label by My Green Lab, a non-profit devoted to fostering a culture of sustainability in science.
Thermo Fisher Scientific Inc. has released two new SARS-CoV-2 antibody tests: The Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. Thermo Fisher Scientific Inc. is the world leader in providing science services.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5010
Published Date: Jun 13, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are the growing prevalence of autoimmune disease, the rise in the need for early detection of cancer, and the advancement of strategies.
The market size of antibody validation is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are General Electric, Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann La-Roche Ltd, and more.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product type, disease indication, end user and by region.
The monoclonal antibodies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Require high investment, variation included in antibody techniques, and limited life span of host animal are estimated to be the growth hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.